Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2026-03-06 @ 9:18 AM
Study NCT ID:
NCT03082534
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-12
First Post:
2017-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Sponsor:
University of California, San Diego
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-28
Start Date Type:
ACTUAL
Primary Completion Date:
2025-11-19
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05
Completion Date Type:
ESTIMATED
First Submit Date:
2017-02-28
First Submit QC Date:
None
Study First Post Date:
2017-03-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-09
Last Update Post Date:
2025-06-12
Last Update Post Date Type:
ACTUAL